Iho Corp

1. Radius Health, Inc. $397,006 14 payments
2. Pfizer Inc. $345,610 39 payments
3. Daiichi Sankyo Inc. $296,758 30 payments
4. Boehringer Ingelheim Pharmaceuticals, Inc. $191,902 5 payments
5. Array BioPharma Inc. $111,524 10 payments
6. AstraZeneca Pharmaceuticals LP $75,794 6 payments
7. EMD Serono, Inc. $57,827 9 payments
8. Genmab U.S., Inc. $40,125 6 payments
9. Stemline Therapeutics Inc. $36,763 28 payments
10. Merck Healthcare KGaA $28,180 6 payments

1. A Randomized Doubleblind Phase 3 Study of Avelumab in Combination With Standard of Care Chemoradiotherapy Cisplatin Plus Definitive Radiation Therapy Versus Standard of Care Chemoradiotherapy in the Frontline Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck $231,983 22 payments
2. A Randomized, Multicenter, Phase 2 Study Of Elacestrant (rad1901) Versus Investigators Choice Of Fulvestrant Or Aromatase Inhibitor Therapy For The Treatment Of Postmenopausal Women With Er+/her2- Breast Cancer $220,403 11 payments
3. Ds1062-A-U304 $182,528 19 payments
4. A Randomized, Multicenter, Phase 2 Study of Elacestrant (Rad1901) Versus Investigators Choice of Fulvestrant Or Aromatase Inhibitor Therapy for the Treatment of Postmenopausal Women With Er+/Her2- Breast Cancer $156,852 2 payments
5. Brightline-4 $140,629 1 payment
6. A Randomized Openlabel Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab Msb0010718c in Combination With Andor Following Chemotherapy in Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100 $106,600 15 payments
7. A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors $106,224 4 payments
8. Ds1062-A-U301 $59,800 6 payments
9. Phase 2 HR+ breast cancer xentuzumab + everolimus $51,272 4 payments
10. A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) $40,445 4 payments

1. Professional salary support $15,526 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.